Board summary
Key figures
46,361
Registered population
60.1% aged 18–64
20.1%
Aged 65+
ICB 24.3% · England 17.9%
4.2%
Ethnic minority (non-White)
1.8% Asian · England 9.6%
7.2%
In IMD quintile 1
ICB 10.9% · England 21.0%
~3,177
Core20 residents (est.)
Resident basis; registered basis ~3,347 · see page 3
8,274
Hypertension register
+19.80% in 3 yrs · England +5.60%
525
SMI register
30.4% of Herefordshire, County of (LAD)'s
1,193
COPD register
Reviews +19.70% in 3 yrs
Forecast to 2030
11,574
Hypertension patients, 2030
+3,300 on today
95.7%
QRISK ≥20% on statins, 2030
+12.51pp over 3 yrs
5.0%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Under-80 blood pressure control trails comparators.
Under-80 hypertension control is 57.8% (England 67.8%, ICB 67.1%, Herefordshire 65.7%) after a -11.8% three-year change (England +3.2%) despite 89.8% BP recording.
Asthma annual reviews and SMI checks lag.
Asthma review coverage is 63.8% (England 65.7%), leaving about 1,100 of 2,994 patients unreviewed, while SMI BP checks are 78.8% (England 83.4%).
Rapid three-year growth in high-risk lipid therapy.
Lipid-lowering therapy for QRISK ≥ 20% rose +26.4% over 2023 to 2025 (England +6.2%) to 59.9%, while COPD annual reviews rose +19.7% to 76.0%.
Population, age and ethnicity
With 20.1% aged 65+, the PCN concentrates substantial older and inclusion health cohorts
Operating as Hereford Medical Group, the PCN serves 46,361 registered patients, with 20.1% (9,311 patients) aged 65+, below Herefordshire (28.3%) and the ICB (24.3%), but above England (17.9%). Patients aged 0-17 comprise 19.8% (9,183), exceeding Herefordshire (16.5%), the ICB (17.8%) and England (19.6%). Census resident ethnicity is 95.8% White (Herefordshire 96.9%, ICB 94.6%, England 81.1%) and 1.8% Asian (Herefordshire 1.2%, ICB 2.6%, England 9.6%), though Census resident context does not reflect practice registrations.
Age profile
65+: ICB 24.3%, England 17.9%
Ethnicity
Older people · falls rows are Herefordshire, County of (LAD) local-authority (LA) data, not PCN
| Measure | Local | West Midlands | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Herefordshire LA) | 1,472 | 1,847 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 77.3% | — | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 54.1% | — | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Herefordshire LA) | 772 | 922 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Herefordshire LA) | 10.4 | 17.5 | 14.8 | 2022‑24 |
Deprivation and Core20
A 7.2% Core20 share masks an estimated 3,177 residents living in deprived deciles
The PCN has an average IMD decile of 5.9 and a Core20 share of 7.2%, below Herefordshire (7.8%), the ICB (10.9%) and England (21.0%). However, an estimated 3,177 residents live in national IMD deciles 1 and 2, including 784 children aged 0-17 and 1,943 adults aged 18-64. Practice list-share estimates indicate 3,347 patients on a different base. Low average deprivation across the footprint may conceal concentrated pockets of neighbourhood deprivation.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
525
SMI register
1.10% recorded prevalence
323
Learning disability register
0.68% recorded prevalence
33
Care homes, 894 beds
In the PCN catchment
8.7%
Provide unpaid care
Herefordshire, County of (LAD), Census 2021
The PCN records 525 severe mental illness patients (1.1% prevalence; Herefordshire 0.9%, ICB 0.8%, England 1.0%), representing 30.4% of the county register, alongside 323 learning disability patients (0.7%; Herefordshire 0.6%, ICB 0.6%, England 0.6%). Its catchment includes 33 care homes with 894 beds, though bed capacity does not establish registered resident numbers. Holding 30.4% of the county SMI register indicates a substantial inclusion caseload, though crude prevalence does not establish.
Severe mental illness: physical health checks
Across 525 patients on the severe mental illness register, 78.8% received a 12-month blood pressure check (England 83.4%) and 81.4% had a BMI recorded (England 82.1%). Dedicated recall could address cardiometabolic monitoring gaps.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
8,274
Hypertension register
+19.80%
Register growth, 3 yrs
Herefordshire, County of (LAD) +10.36% · England +5.60%
−7.73pp
BP control, under 80
≤140/90 · −2.11pp aged 80+
+3,300
More patients by 2030
Forecast 11,574 (24.97%)
Hypertension case-finding and control
Hypertension register prevalence is 17.4% (8,274 patients), rising +19.8% over 2023 to 2025 (England +5.6%). While 89.8% had a recent blood pressure reading (England 90.0%), patients treated to target fell 8.4% (England +3.6%) to 62.4% (England 70.3%). Among patients under 80, control fell 11.8% over 2023 to 2025 (England +3.2%) to 57.8%, below England (67.8%), Herefordshire (65.7%) and the ICB (67.1%). Crude prevalence is unadjusted for age and baseline periods are unstated. With blood pressure control below England despite high monitoring reach, clinical review and medication titration for adults under 80 are key operational priorities.
Lipids and statins
Lipid-lowering therapy for QRISK ≥ 20% rose +26.4% over 2023 to 2025 (England +6.2%) to 59.9% (England 63.6%). For diabetes with cardiovascular disease, statin coverage is 76.2% (England 84.4%). Secondary prevention and high-risk lipid recall remain priorities to narrow gaps against England.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 63,045 | £2.80 | £2.17 | £1.86 | £176,526 |
| Cardiovascular (all), 2025 | 94,858 | £4.38 | £4.41 | £3.33 | £415,478 |
In 2026, lipid-regulating prescribing totalled 63,045 items at £2.80 per item (£176,526 spend), above England (£1.86), Herefordshire (£2.44) and the ICB (£2.17), spending £59,262 more than at England's unit cost. Higher unit costs may reflect formulary selection, which prescribing review could test.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+7.74%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+8.22%
Asthma prevalence, PCN 3-yr % change
COPD annual review completion reached 76.0% across 1,193 patients, rising +19.7% over 2023 to 2025 (England +2.8%). In contrast, asthma reviews trail at 63.8% (England 65.7%, ICB 66.4%), leaving about 1,100 of 2,994 registered patients without an annual review. Furthermore, asthma management items prescribed for ages 5-19 sit at 1,189 per 1,000, below England's 1,488 and the ICB's 1,553. Lower paediatric prescribing alongside review shortfalls may reflect unreviewed maintenance, which clinical record audits could test.
Cancer register and children's immunisation
The cancer register records 1,983 patients (4.2% prevalence, England 3.8%). In childhood immunisations, 12-month 6-in-1 coverage is 98.2%, but pre-school completion drops: in the age-5 cohort of 123 children, MMR1 reaches 95.1% while MMR2 falls to 87.0% (an 8.1 pp difference, 8 pp below the 95.0% target), and the 4-in-1 booster reaches 83.7% (11.3 pp below the 95.0% target).
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
56.2%
Herefordshire and Worcestershire ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~770
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Herefordshire and Worcestershire ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 52.4% | 53.2% | 23% | 706 |
| Bowel | 51.4% | 47.0% | 15% | 657 |
| Breast | 88.9% | 85.4% | 28% | 611 |
| Lung | 32.1% | 33.8% | 13% | 473 |
| Skin cancer | 86.3% | 87.8% | 13% | 314 |
At system level (NHS Herefordshire and Worcestershire ICB in 2022), 56.2% of cancers with a known stage were diagnosed early at stage 1 or 2 (2,285 of 4,068; England 55.3%), 18.8 percentage points below the 75.0% national ambition by 2028. Stage was known for 68.0% of registrations (4,068 of 5,984), requiring about 770 extra early diagnoses annually. For the PCN (1,983 cancer patients, 4.2% prevalence), cervical screening at ages 25 to 49 is 60.5% (ICB 70.9%, England 66.8%), falling 3.0% over 2023 to 2025 (England -1.0%), while breast screening is 70.8% (ICB 75.0%). Screening recall supports earlier cancer detection.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026, Wye Valley NHS Trust achieved 85.1% on the cancer 62-day standard (standard 85.0%), compared with Worcestershire Acute Hospitals NHS Trust (53.0%), Gloucestershire Hospitals NHS Foundation Trust (74.6%), NHS Herefordshire and Worcestershire Integrated Care Board (61.7%) and England (71.2%). On the 28-day faster diagnosis standard, Wye Valley reached 86.5% (standard 75.0%; ICB 83.0%, England 79.3%). For diagnostics, 19.3% waited 6+ weeks at Wye Valley (England 23.1%), but colonoscopy (40.0%, England 30.8%) and flexi sigmoidoscopy (48.7%, England 32.1%) show longer waits.
| Pathways within standard (%) | Wye Valley | Worcestershire Acute | Gloucestershire | Herefordshire and Worcestershire ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 86.52 | 82.50 | 74.43 | 83.05 | 79.32 |
| 31-day treatment (96%) | 96.25 | 86.98 | 94.66 | 89.95 | 92.50 |
| 62-day referral to treatment (85%) | 85.14 | 52.99 | 74.59 | 61.71 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Wye Valley | Worcestershire Acute | Gloucestershire | England |
|---|---|---|---|---|
| MRI | 18.23 | 22.51 | 15.96 | 21.40 |
| CT | 0.16 | 11.09 | 7.44 | 9.92 |
| Echocardiography | 30.24 | 10.25 | 56.17 | 28.48 |
| Colonoscopy | 40.00 | 9.91 | 40.00 | 30.83 |
| Gastroscopy | 26.09 | 9.53 | 31.55 | 29.02 |
| All 15 DM01 tests | 19.35 | 30.61 | 18.34 | 23.14 |
| Community services activity | Herefordshire, County of residents | Herefordshire and Worcestershire ICB |
|---|---|---|
| Care contacts | 43,135 | 124,085 |
| Referrals | 5,970 | 23,130 |
| Patients with a contact | 9,550 | 30,665 |
Community services (residents of Herefordshire, County of), Jun 2026 (provisional). In Jun 2026, provisional community services recorded 5,970 referrals and 43,135 care contacts for Herefordshire residents (ICB: 23,130 referrals; 124,085 contacts). Contacts were concentrated in older age groups, with adults aged 65+ accounting for 67.4% (29,080 contacts), alongside 6,460 contacts for ages 0-18. These figures represent county-level resident activity across submitting providers, rather than direct PCN-managed intermediate care delivery.
Practice variation and patient experience
Phone access at 26.6% trails England's 56.9% despite 98.0% overall QOF achievement
For 2025/26, Hereford Medical Group achieved 98.0% overall QOF points (England 92.5%), including 100.0% in the clinical domain (England 97.1%) and 84.7% in vaccination and immunisation (England 55.2%). The personalised care adjustment rate across all domains was 10.2%, in line with England's 10.0%. High recorded clinical attainment does not remove the need to verify population reach.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Hereford Medical | 169 | 7.2 | 26.6% | 62.0% | 55.8% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Ten of 25 measures trail England, led by falling blood pressure control
Across 25 compared measures, 10 trail England's three-year change over 2023 to 2025. The widest relative lags are in blood pressure control under age 80, which fell 11.8% (England +3.2%), hypertension control to threshold, down 8.4% (England +3.6%), and heart failure annual reviews, which rose +0.8% (England +8.7%). Smoking cessation offers fell 5.0 pp (England +0.1 pp). Conversely, statins for high QRISK rose +26.4% (England +6.2%), COPD reviews rose +19.7% (England +2.8%), and diabetes statins rose +14.6% (England +2.1%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
BP control, under 80
Hypertension treated to target
Heart failure reviews
Smoking support (SMI)
BP control, 80+
QRISK statin treatment
COPD reviews
Diabetes statin (no CVD)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Herefordshire, County of (LAD) | Asset | PCN | Herefordshire, County of (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 33 (894 beds) | n/a | Schools (catchment) | 68 | n/a |
| Children's centres | 3 | 7 | Places of worship | 79 | 341 |
| Libraries | 3 | 9 | Day centres (VCS) | 1 | 1 |
| Carers support groups (VCS) | 1 | 1 | Primary schools (LA maintained) | 11 | 43 |
| Primary academies | 14 | 28 | Special schools | 1 | 4 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Hypertension medication titration and control
Under-80 BP control is 57.8%, 10.1 pp below England's 67.8% (ICB 67.1%), after falling 11.8% over 2023 to 2025 (England +3.2%); overall control is 62.4% across 8,274 patients. For discussion: a pharmacist-led or nurse-led titration clinic could review patients under 80 with readings above 140/90 mmHg. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 2
Asthma annual review and prescribing recall
Asthma 12-month review coverage is 63.8% across 2,994 registered patients, trailing Herefordshire (64.8%), England (65.7%) and the ICB (66.4%), leaving 1,084 (about 1,100) patients unreviewed. For discussion: the PCN could run single-template asthma recall offering flexible slots and reviewing inhaler prescribing alongside annual checks. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
SMI physical health check outreach
Across 525 SMI patients (30.4% of Herefordshire's register), 12-month BP checks sit at 78.8%, 4.6 pp below England's 83.4% (ICB 82.7%), and BMI recording is 81.4% (England 82.1%). For discussion: the PCN could introduce combined physical health check appointments and dedicated outreach for non-attenders. Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Targeted Core20 outreach audit (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Physical health check recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension treatment titration audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school immunisation call-recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening uptake initiative (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Telephony and triage capacity review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Hypertension medication titration and control (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients with a recent BP reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 2 · Asthma annual review and prescribing recall (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 3 · SMI physical health check outreach (p12) | Severe mental illness register · Severe mental illness: QOF prevalence · SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
